Loading clinical trials...
Loading clinical trials...
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Conditions
Interventions
LUM/IVA
LUM/IVA
Locations
60
United States
Birmingham, Alabama, United States
Tucson, Arizona, United States
Long Beach, California, United States
Palo Alto, California, United States
Aurora, Colorado, United States
Wilmington, Delaware, United States
Start Date
August 1, 2015
Primary Completion Date
August 1, 2018
Completion Date
April 1, 2020
Last Updated
May 24, 2021
NCT02417740
NCT06616857
NCT02740868
NCT07108153
NCT07274631
NCT07303621
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions